Skip to main
ACLX

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 7%
Hold 79%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc is noted for its promising collaboration with Gilead, which offers a competitive edge through advanced cell therapy manufacturing and patient support, thereby potentially boosting market position and sales. The anticipated approval of Anito-cel for multiple myeloma patients by the end of 2026 is expected to lead to a highly successful product launch and a robust market presence, with peak global sales projections reaching $7 billion. Furthermore, the management's effective execution in developing Anito-cel and the favorable clinical outcomes compared to existing treatments enhance the company's overall value proposition to shareholders.

Bears say

The analysis indicates that Arcellx Inc. faces significant risks related to its clinical-stage development and potential commercial viability, as evidenced by the downgrade of its shares to Hold based on an acquisition proposal from Gilead Sciences (GILD) valued at $7.8 billion. Concerns about the effectiveness of its D-Domain CAR-T therapy platform and the ARC-SparX platform create uncertainty regarding the generation of successful clinical candidates, which may hinder future growth. Additionally, the company is vulnerable to various risks, including competition, pricing pressures, and regulatory challenges, all of which could severely impact its valuation and stock performance going forward.

Arcellx (ACLX) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 7% recommend Buy, 79% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Hold based on their latest research and market trends.

According to 14 analysts, Arcellx (ACLX) has a Hold consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.